Prognostic Significance for Long-Term Outcomes Following Radical Prostatectomy in Men with Prostate Cancer: Evaluation with Prostate Imaging Reporting and Data System Version 2
- Author:
Ran KIM
1
;
Chan Kyo KIM
;
Jung Jae PARK
;
Jae Hun KIM
;
Seong Il SEO
;
Seong Soo JEON
;
Hyun Moo LEE
Author Information
- Publication Type:Original Article
- Keywords: Prostate cancer; Prostatectomy; Prognosis; PI-RADS; Outcome
- MeSH: Disease Progression; Disease-Free Survival; Follow-Up Studies; Humans; Information Systems; Magnetic Resonance Imaging; Male; Multivariate Analysis; Passive Cutaneous Anaphylaxis; Prognosis; Proportional Hazards Models; Prostate; Prostatectomy; Prostatic Neoplasms; Recurrence; Retrospective Studies
- From:Korean Journal of Radiology 2019;20(2):256-264
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To retrospectively determine whether the use of the Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) helps predict long-term outcomes for prostate cancer (PCa) patients following radical prostatectomy (RP). MATERIALS AND METHODS: A total of 166 patients with localized PCa evaluated with multiparametric magnetic resonance imaging (mpMRI) at 3T before RP were enrolled. Three groups were created based on PI-RADS v2 score used to predict clinical outcomes: group A, ≥ 3; group B, ≥ 4; group C, 5. We calculated biochemical recurrence-free survival (RFS) and progression-free survival (PFS). Cox proportion hazards models were used to identify variables predictive of biochemical recurrence and disease progression. RESULTS: During a median follow-up of 9.1 years, biochemical recurrence occurred in 67 patients (40.4%) and disease progression occurred in 55 patients (33.1%). In all groups, 10-year RFS and 10-year PFS were significantly lower for PI-RADS scores ≥ 3, ≥ 4 and 5 than for score < 3, < 4 and < 5 (p <0.05), respectively. In multivariate analysis, PI-RADS score ≥ 3 and score 5 were significant independent risk marker for biochemical recurrence (hazard ratio [HR] = 5.58, p = 0.018; HR = 1.75, p = 0.033) and disease progression (HR = 3.99, p = 0.047; HR = 2.31, p = 0.040). Moderate inter-observer agreement was seen for PI-RADS scoring. CONCLUSION: PI-RADS v2 may be used to predict long-term outcomes following RP in PCa.
